Neuronanomedicine

描述（由申请人提供）：神经纳米医学是一个新的研究领域，定义为用于诊断和治疗神经系统退行性、炎症、感染、血管、成瘾、行为和代谢疾病的纳米技术的开发和转化。该研究学科是跨学科的，处于起步阶段。需要克服障碍，以实现成功，改善已知的血脑屏障限制，纳米毒理学，低效的药物靶向病变的大脑区域，并达到特定的神经亚细胞区室。所有这些都给实地工作带来了重大挑战。为了促进成功的研究成果，我们计划将来自不同背景的科学家聚集在一起，从事神经元医学，提出研究结果，这将有助于定义该领域，同时也为学员提供直接参与当前和未来讨论的机会。美国纳米医学协会（ASNM）通过将2013年会议的重点放在神经纳米医学的多方面学科上，发挥了领导作用。自2008年成立以来，ASNM已经准备好承担这一角色，因为该协会的目标一直是纳米技术的临床转化。这些目标将是 在一个开放的论坛讨论，其中将包括，但不限于，生物伦理，安全和毒性，知识产权和产品商业化培育。会议的一个主要焦点是 将早期的职业研究者引入转化神经元医学领域。ASNM强调快速翻译方法的创新性和实用性，这与会议的目标相一致，即合并不同的学科和方法，以促进从产品开发到实验室和动物试验，最终到人体临床试验的合作研究。该提案由经验丰富的医生兼科学家霍华德·金德尔曼博士领导，利用了一个经验丰富、纪律严明的董事会。总的来说，对神经系统的关注代表了ASNM领导层的演变和会议方向的进一步变化。它将使该领域的新指令能够跟上纳米技术研究范围的需求。

DESCRIPTION (provided by applicant): Neuronanomedicine is a new research field defined as the development and translation of nanotechnology for diagnosis and treatment of degenerative, inflammatory, infectious, vascular, addictive, behavioral and metabolic disorders of the nervous system. The research discipline is interdisciplinary and in its infancy. Hurdles need be overcome for success to be realized that improve known blood brain barrier restrictions, nanotoxicologies, inefficient drug targeting to diseased brain regions and in reaching specific neural subcellular compartments. These all pose significant challenges to the field. To facilitate successful research outcomes we plan to bring together scientists from divergent backgrounds engaged in neuronanomedicine to present research findings that will help define the field while also facilitating opportunities for trainees to directly engage in currnt and future discussions. The American Society for Nanomedicine (ASNM) has taken a leadership role by focusing its 2013 meeting to the multifaceted discipline of neuronanomedicine. The ASNM is well positioned to assume this role as the society's goals since its 2008 inception has rested in clinical translation of nanotechnologies. Such goals will be fostered in an open forum discussion that will include, but is not limited to, bioethics, safety an toxicity, intellectual property, and product commercialization. A major focus for the conference is in bringing early career investigators into the field of translational neuronanomedicine. ASNM's emphasis on innovation and practicality of approaches for speedy translation parallels the conference goals on merging divergent disciplines and approaches to facilitate collaborative research from product development to laboratory and animal testing and ultimately to human clinical trials. The proposal while led by an experienced physician-scientist, Dr. Howard Gendelman, takes advantage of a highly seasoned broad-disciplined board. Overall, the focus on the nervous system represents an evolution of ASNM leadership and a further change in direction for the meeting. It will enable new directives in the field to keep abreast with needs an research scope in nanotechnology.